A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
Authors
Keywords
Exenatide once weekly, GLP-1 receptor agonist, Network meta-analysis, Type 2 diabetes
Journal
Diabetes Therapy
Volume 7, Issue 1, Pages 27-43
Publisher
Springer Nature
Online
2016-02-17
DOI
10.1007/s13300-016-0155-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Emerging New Therapies for the Treatment of Type 2 Diabetes Mellitus: Glucagon-like Peptide-1 Receptor Agonists
- (2015) Christopher A. Lindamood et al. CLINICAL THERAPEUTICS
- GLP-1 Receptor Agonists
- (2015) Curtis Triplitt et al. DIABETES EDUCATOR
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2014) Silvio E. Inzucchi et al. DIABETES CARE
- HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin
- (2014) Bo Ahrén et al. DIABETES CARE
- Improved real-world glycaemic outcomes with liraglutide versus other incretin-based therapies in type 2 diabetes
- (2014) W. C. Lee et al. DIABETES OBESITY & METABOLISM
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
- (2014) Kathleen M Dungan et al. LANCET
- Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial
- (2014) Michaela Diamant et al. Lancet Diabetes & Endocrinology
- Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)
- (2013) J. Rosenstock et al. DIABETES CARE
- Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)
- (2013) Bo Ahrén et al. DIABETES CARE
- Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1)
- (2013) G. B. Bolli et al. DIABETIC MEDICINE
- Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial
- (2013) B. Charbonnel et al. DIABETOLOGIA
- Efficacy and Safety Profile of Exenatide Once Weekly Compared With Insulin Once Daily in Japanese Patients With Type 2 Diabetes Treated With Oral Antidiabetes Drug(s): Results From a 26-Week, Randomized, Open-Label, Parallel-Group, Multicenter, Noninferiority Study
- (2012) Nobuya Inagaki et al. CLINICAL THERAPEUTICS
- Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir: Randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas
- (2012) M. Davies et al. DIABETES CARE
- Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes
- (2012) T. Ridge et al. DIABETES OBESITY & METABOLISM
- A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo
- (2012) D. A. Scott et al. DIABETES OBESITY & METABOLISM
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
- (2012) John B Buse et al. LANCET
- Evidence Synthesis for Decision Making 2
- (2012) Sofia Dias et al. MEDICAL DECISION MAKING
- Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus
- (2012) Linong Ji et al. Journal of Diabetes Investigation
- Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany
- (2012) Lesley-Ann Miller et al. JOURNAL OF MEDICAL ECONOMICS
- Efficacy and Safety of Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Compared with Exenatide Twice Daily and Sitagliptin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
- (2011) Nicole R Pinelli et al. ANNALS OF PHARMACOTHERAPY
- Exenatide Twice Daily Versus Premixed Insulin Aspart 70/30 in Metformin-Treated Patients With Type 2 Diabetes: A randomized 26-week study on glycemic control and hypoglycemia
- (2011) B. Gallwitz et al. DIABETES CARE
- Encapsulation of Exenatide in Poly-(d,l-Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes
- (2011) Mary Beth DeYoung et al. Diabetes Technology & Therapeutics
- Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients
- (2011) Giuseppe Derosa et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
- (2011) Thomas Blevins et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of Exenatide Plus Rosiglitazone on -Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin
- (2010) R. A. DeFronzo et al. DIABETES CARE
- DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
- (2010) J. B. Buse et al. DIABETES CARE
- Exenatide Versus Glibenclamide in Patients with Diabetes
- (2010) G. Derosa et al. Diabetes Technology & Therapeutics
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
- (2010) Richard M Bergenstal et al. LANCET
- Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
- (2010) Richard E Pratley et al. LANCET
- Checking consistency in mixed treatment comparison meta-analysis
- (2010) S. Dias et al. STATISTICS IN MEDICINE
- How Far Do You Go? Efficient Searching for Indirect Evidence
- (2009) Neil Hawkins et al. MEDICAL DECISION MAKING
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
- (2008) Daniel J Drucker et al. LANCET
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now